Odin Naderer

982 total citations
32 papers, 729 citations indexed

About

Odin Naderer is a scholar working on Epidemiology, Infectious Diseases and Oncology. According to data from OpenAlex, Odin Naderer has authored 32 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 12 papers in Infectious Diseases and 12 papers in Oncology. Recurrent topics in Odin Naderer's work include Peptidase Inhibition and Analysis (9 papers), Pneumocystis jirovecii pneumonia detection and treatment (8 papers) and Antibiotic Resistance in Bacteria (6 papers). Odin Naderer is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Pneumocystis jirovecii pneumonia detection and treatment (8 papers) and Antibiotic Resistance in Bacteria (6 papers). Odin Naderer collaborates with scholars based in United States, United Kingdom and Germany. Odin Naderer's co-authors include Amy Cutrell, Seth Hetherington, Helen Steel, Gill Pearce, Keith A. Rodvold, Joseph Bertino, Étienne Dumont, A N Nafziger, Milena Kurtinecz and John Zhu and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Critical Care Medicine.

In The Last Decade

Odin Naderer

30 papers receiving 697 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Odin Naderer United States 12 287 236 217 109 92 32 729
Rosa María López Spain 18 534 1.9× 86 0.4× 326 1.5× 134 1.2× 44 0.5× 44 888
M. F. Kergueris France 12 139 0.5× 208 0.9× 138 0.6× 38 0.3× 41 0.4× 32 533
Ólanrewaju O. Okusanya United States 18 153 0.5× 362 1.5× 286 1.3× 30 0.3× 81 0.9× 38 845
Lillian Ting Canada 15 537 1.9× 135 0.6× 273 1.3× 303 2.8× 54 0.6× 26 1.1k
Leonor Pou Spain 17 454 1.6× 63 0.3× 293 1.4× 118 1.1× 54 0.6× 29 900
Jan Sahai Canada 15 532 1.9× 333 1.4× 360 1.7× 128 1.2× 165 1.8× 35 1.1k
L. Pou Spain 15 251 0.9× 104 0.4× 248 1.1× 17 0.2× 56 0.6× 26 521
Margaret Tawadrous United States 17 372 1.3× 244 1.0× 361 1.7× 77 0.7× 93 1.0× 47 1.1k
Manuel Crespo Spain 15 207 0.7× 118 0.5× 264 1.2× 151 1.4× 28 0.3× 47 776
Sorin Rugină Romania 11 441 1.5× 555 2.4× 249 1.1× 259 2.4× 74 0.8× 65 1.6k

Countries citing papers authored by Odin Naderer

Since Specialization
Citations

This map shows the geographic impact of Odin Naderer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Odin Naderer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Odin Naderer more than expected).

Fields of papers citing papers by Odin Naderer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Odin Naderer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Odin Naderer. The network helps show where Odin Naderer may publish in the future.

Co-authorship network of co-authors of Odin Naderer

This figure shows the co-authorship network connecting the top 25 collaborators of Odin Naderer. A scholar is included among the top collaborators of Odin Naderer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Odin Naderer. Odin Naderer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arumugham, Thangam, et al.. (2025). Effect of Severe Renal Impairment on Dordaviprone (ONC201) Pharmacokinetics. Drugs in R&D. 25(3). 253–261. 1 indexed citations
2.
Arumugham, Thangam, et al.. (2025). A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults. British Journal of Clinical Pharmacology. 91(9). 2605–2612. 3 indexed citations
3.
4.
5.
Arumugham, Thangam, et al.. (2024). Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co‐Administration of the Proton‐Pump Inhibitor Rabeprazole. The Journal of Clinical Pharmacology. 65(4). 520–526. 2 indexed citations
6.
Lasky, Joseph A., Jyotsna Fuloria, Marion E. Morrison, et al.. (2020). Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. Advances in Therapy. 38(1). 782–791. 13 indexed citations
7.
Naderer, Odin, et al.. (2018). 1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects. Open Forum Infectious Diseases. 5(suppl_1). S438–S439. 2 indexed citations
8.
Wire, Mary Beth, et al.. (2017). Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects. Open Forum Infectious Diseases. 4(suppl_1). S311–S311. 8 indexed citations
9.
Zhu, John, Chester L. Bowen, Odin Naderer, et al.. (2014). Investigation of Metabolism and Disposition of GSK1322322, a Peptidase Deformylase Inhibitor, in Healthy Humans Using the Entero-Test for Biliary Sampling. Drug Metabolism and Disposition. 42(8). 1314–1325. 9 indexed citations
10.
Arat, Seda, Aaron Spivak, Stephanie Van Horn, et al.. (2014). Microbiome Changes in Healthy Volunteers Treated with GSK1322322, a Novel Antibiotic Targeting Bacterial Peptide Deformylase. Antimicrobial Agents and Chemotherapy. 59(2). 1182–1192. 12 indexed citations
11.
Naderer, Odin, Étienne Dumont, Jie Zhu, Milena Kurtinecz, & Lauren Jones. (2013). Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study. Journal of Antimicrobial Chemotherapy. 68(8). 1901–1909. 13 indexed citations
12.
Naderer, Odin. (2008). Nasal Decolonization of Persistent Staphylococcus aureus (SA) Carriers with Twice Daily Application of Retapamulin Ointment, 1%, (RET) for 3 or 5 Days. 46th Annual Meeting. 3 indexed citations
13.
Iles‐Smith, Heather, Ya‐Chi Chen, Odin Naderer, et al.. (2007). Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end‐stage renal failure. British Journal of Clinical Pharmacology. 64(6). 738–744. 8 indexed citations
14.
Naderer, Odin, Robert E. Dupuis, Erin L. Heinzen, et al.. (2005). The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil. The Journal of Clinical Pharmacology. 45(2). 219–226. 60 indexed citations
15.
16.
Wood, Robin, Keikawus Arastéh, Hans‐Jürgen Stellbrink, et al.. (2003). Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrobial Agents and Chemotherapy. 48(1). 116–123. 36 indexed citations
17.
Eron, Joseph J., et al.. (2002). Effects of Formulation and Dosing Strategy on Amprenavir Concentrations in the Seminal Plasma of Human Immunodeficiency Virus Type 1–Infected Men. Clinical Infectious Diseases. 35(6). 760–762. 13 indexed citations
18.
Hetherington, Seth, et al.. (2001). Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clinical Therapeutics. 23(10). 1603–1614. 299 indexed citations
19.
Gentry, Chris A., Keith A. Rodvold, Richard Novák, Ronald C. Hershow, & Odin Naderer. (1997). Retrospective Evaluation of Therapies for Staphylococcus aureus Endocarditis. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(5). 990–997. 61 indexed citations
20.
Schumock, Glen T., Susan Raber, Stephanie Y. Crawford, Odin Naderer, & Keith A. Rodvold. (1995). National Survey of Once‐Daily Dosing of Aminoglycoside Antibiotics. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 15(2). 201–209. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosa María López Breakdown of academic impact, for papers by M. F. Kergueris Breakdown of academic impact, for papers by Ólanrewaju O. Okusanya Breakdown of academic impact, for papers by Lillian Ting Breakdown of academic impact, for papers by Leonor Pou Breakdown of academic impact, for papers by Jan Sahai Breakdown of academic impact, for papers by L. Pou Breakdown of academic impact, for papers by Margaret Tawadrous Breakdown of academic impact, for papers by Manuel Crespo Breakdown of academic impact, for papers by Sorin Rugină
Rankless by CCL
2026